MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

2016 Medtech Company of the Year Finalists: 23andMe

TAGS: News
23andMeThe provider of affordable genetic tests for the masses has been one of the great comeback stories in medtech.

23andMe

23andMe resumed selling its home genetic tests last year.

The provider of affordable genetic tests for the masses has been one of the great comeback stories in medtech. In 2013, 23andMe faced an especially scathing FDA warning letter that accused it of marketing its tests to provide "'health reports on 254 diseases and conditions" that could potentially cause people to make medical decisions that were not in their interests. As a result, the Silicon Valley company had to scale back its offering to ancestry tests. 

CEO Anne Wojcicki, though, made resolution with FDA a priority.

"It was just a question of saying, 'You know what? We entirely need to refocus. We need to hire the right people. We had a major miscommunication. We need to make sure we're executing the right way," she told Bloomberg last year.

The company over time has been able to reintroduce consumer genetic tests related to health, this time with FDA's blessing. The company's $199 health and ancestry test, for example, lets customers know whether they are carrying genes related to cystic fibrosis, sickle cell anemia, and hereditary hearing loss. 

          
Don't miss the BIOMEDevice San Jose conference and expo, December 7 & 8, 2016.
[image courtesy of 23ANDME]
Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish